The use of new medications such as GLP-1 analogs, SGLT-2 inhibitors for diabetes and medications for dyslipidemia has been increasing with time and should be accounted for in the control of disease, in addition to lifestyle behaviors. This evidence concerns the gene SLC5A2 and diabetes mellitus.